Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine | Zendy

David V. Glidden | Zendy; Kathleen Mulligan | Zendy; Vanessa McMahan | Zendy; Peter L. Anderson | Zendy; Juan V. Guanira | Zendy; Suwat Chariyalertsak | Zendy; Susan Buchbinder | Zendy; LindaGail Bekker | Zendy; Mauro Schechter | Zendy; Beatriz Grinsztejn | Zendy; Robert M. Grant | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine

Author(s) -

David V. Glidden,

Kathleen Mulligan,

Vanessa McMahan,

Peter L. Anderson,

Juan V. Guanira,

Suwat Chariyalertsak,

Susan Buchbinder,

LindaGail Bekker,

Mauro Schechter,

Beatriz Grinsztejn,

Robert M. Grant

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy083

Subject(s) - medicine , tenofovir , emtricitabine , pre exposure prophylaxis , pharmacology , human immunodeficiency virus (hiv) , antiretroviral therapy , virology , viral load , syphilis , men who have sex with men

Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown to have a more favorable metabolic profile than other drugs in its class. However, the metabolic effects of TDF in preexposure prophylaxis (PrEP) are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research